Crossmark

Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: a systematic review and meta-analysis of 2251 patients

Crossref DOI link: https://doi.org/10.1007/s11255-024-04316-x

Published Online: 2024-12-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abo Elnaga, Ahmed A.

Serag, Ibrahim

Alsaied, Mohamed A.

Khalefa, Basma Badrawy

Rajput, Jaisingh

Ramadan, Shrouk

Elettreby, Abdelrahman M.
License Information

Text and Data Mining valid from 2024-12-19

Version of Record valid from 2024-12-19
More Information

Article History

Received: 25 July 2024

Accepted: 26 November 2024

First Online: 19 December 2024

Declarations

:

: The authors have no conflicts of interest to declare.

: Not applicable.

Document is current

Any future updates will be listed below